BioLineRx (BLRX) Stock Price, News & Analysis

Company Overview

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Key Stats

• Today's Range: $0.52 to $0.57
• 50-Day Range: $0.40 to $0.66
• 52-Week Range: $0.39 to $1.89
• Volume: 362,986 shs
• Average Volume: 352,431 shs
• Market Capitalization: $43.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Buy

BioLineRx Stock Analysis - MarketRank™

BioLineRx scored higher than 39% of companies evaluated by MarketBeat, and ranked 766th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

BioLineRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BioLineRx has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for BioLineRx are expected to decrease in the coming year, from ($0.03) to ($0.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioLineRx is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioLineRx is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioLineRx has a P/B Ratio of 3.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.33% of the outstanding shares of BioLineRx have been sold short.

Short Interest Ratio / Days to Cover

BioLineRx has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioLineRx has recently increased by 70.58%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioLineRx does not currently pay a dividend.

Dividend Growth

BioLineRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.33% of the outstanding shares of BioLineRx have been sold short.

Short Interest Ratio / Days to Cover

BioLineRx has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioLineRx has recently increased by 70.58%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.17

News Sentiment

BioLineRx has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for BioLineRx this week, compared to 1 article on an average week.

Search Interest

9 people have searched for BLRX on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.

MarketBeat Follows

4 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioLineRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.10% of the stock of BioLineRx is held by insiders.

Percentage Held by Institutions

Only 1.56% of the stock of BioLineRx is held by institutions.

BLRX Stock Analysis - Frequently Asked Questions

How have BLRX shares performed this year?

BioLineRx's stock was trading at $1.57 at the beginning of the year. Since then, BLRX shares have decreased by 65.3% and is now trading at $0.5452.
View the best growth stocks for 2024 here.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) issued its quarterly earnings results on Tuesday, May, 28th. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.28. The biotechnology company had revenue of $6.86 million for the quarter, compared to the consensus estimate of $0.34 million.

Who are BioLineRx's major shareholders?

Top institutional investors of BioLineRx include Atria Investments Inc (0.17%).

How do I buy shares of BioLineRx?

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BioLineRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include Savara (SVRA), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI) and Tesla (TSLA).

Company Calendar

• Last Earnings: 5/28/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BLRX
• CUSIP: N/A
• CIK: 1498403
• Web: www.biolinerx.com
• Phone: (728) 642-9100
• Fax: 972-8642-9101
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.00
• High Stock Price Target: $21.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +3,751.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-60,610,000.00
• Net Margins: N/A
• Pretax Margin: -176.67%
• Return on Equity: -225.62%
• Return on Assets: -51.71%

Debt

• Debt-to-Equity Ratio: 1.34
• Current Ratio: 1.61
• Quick Ratio: 1.49

Sales & Book Value

• Annual Sales: $17.05 million
• Price / Sales: 2.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.18 per share
• Price / Book: 3.03

Miscellaneous

• Outstanding Shares: 79,939,000
• Free Float: 79,060,000
• Market Cap: $43.58 million
• Optionable: Optionable
• Beta: 1.48